Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Sleep Medicine Reports
Erschienen in:

16.06.2023

Valerian for Insomnia on Subjective and Objective Sleep Parameters: a Meta-analysis of Randomized Controlled Trials

verfasst von: Xu Zhang, Yanying Lu, Feiyan Lv, Yan Hu, Zhentao Yao, Yulong Wu, Fuzhi Lian, Jun Yang, Xianrong Xu

Erschienen in: Current Sleep Medicine Reports | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This systematic review and meta-analysis aimed to assess the effects of valerian intervention for insomnia on both subjective and objective sleep parameters.

Recent Findings

Twenty-one RCTs with a total of 1433 participants were retrieved after searching on 6 electronic databases. The results indicated that, for subjective parameters, valerian may have a small to moderate effects on PSQI score (standardized mean differences (SMD), −1.21; 95% CI [−1.92 to −0.51]), self-reported dichotomous outcome of sleep quality (risk ratio (RR) =1.37; 95% CI [1.13 to 1.68]), and self-reported sleep duration (RR=1.27; 95% CI [1.02 to 1.57]). For objective parameters, valerian only have significant effect on the length of non-rapid eye movement (NREM) stage 3 (SMD= 0.89; 95% CI [0.35 to 1.43]) of the patients. Heterogeneity was mainly due to varied study designs, especially in preparation, outcomes measured, duration of follow-up, and populations.

Summary

Valerian intervention for insomnia may improve PSQI scores, subjective dichotomous outcomes of sleep quality and duration, and time of NREM stages 3.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol. 2015;66:143–72.PubMedCrossRef
2.
3.
Freeman D, Sheaves B, Waite F, Harvey AG, Harrison PJ. Sleep disturbance and psychiatric disorders. Lancet Psychiatry. 2020;7(7):628–37.PubMedCrossRef
4.
5.
Jahrami HA, Alhaj OA, Humood AM, Alenezi AF, Fekih-Romdhane F, AlRasheed MM, et al. Sleep disturbances during the COVID-19 pandemic: a systematic review, meta-analysis, and meta-regression. Sleep Med Rev. 2022;62:101591.PubMedPubMedCentralCrossRef
6.
Cunnington D, Junge M. Chronic insomnia: diagnosis and non-pharmacological management. BMJ. 2016;355:i5819.PubMedCrossRef
7.
Soong C, Burry L, Greco M, Tannenbaum C. Advise non-pharmacological therapy as first line treatment for chronic insomnia. BMJ. 2021;372:n680.PubMedCrossRef
8.
Koffel E, Bramoweth AD, Ulmer CS. Increasing access to and utilization of cognitive behavioral therapy for insomnia (CBT-I): a narrative review. J Gen Intern Med. 2018;33(6):955–62.PubMedPubMedCentralCrossRef
9.
Gyllenhaal C, Merritt SL, Peterson SD, Block KI, Gochenour T. Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med Rev. 2000;4(3):229–51.PubMedCrossRef
10.
Wheatley D. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. J Psychopharmacol. 2005;19(4):414–21.PubMedCrossRef
11.
Giedke H, Breyer-Pfaff U. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000;33(6):239.PubMedCrossRef
12.
13.
Abad VC, Guilleminault C. Insomnia in elderly patients: recommendations for pharmacological management. Drugs Aging. 2018;35(9):791–817.PubMedCrossRef
14.
Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505–11.PubMedCrossRef
15.
Taibi DM, Landis CA, Petry H, Vitiello MV. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev. 2007;11(3):209–30.PubMedCrossRef
16.
Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med. 2000;1(2):91–9.PubMedCrossRef
17.
18.
Shinjyo N, Waddell G, Green J. Valerian root in treating sleep problems and associated disorders-a systematic review and meta-analysis. J Evid Based Integr Med. 2020;25:2515690X20967323.PubMedPubMedCentralCrossRef
19.
20.
Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav. 1982;17(1):65–71.PubMedCrossRef
21.
Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med. 1985;2:144–8.CrossRef
22.
Jokar A, Kargosha A, Akarzadeh M, Asadi N, Setoudeh Z. Comparing the influence of relaxation training and consumption of valerian on insomnia of menopause women: a randomized clinical trial. Afr J Tradit Complem. 2016;13(1):40–4.CrossRef
23.
Koetter U, Schrader E, Kaufeler R, Brattstrom A. A randomized, double blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. Phytother Res. 2007;21(9):847–51.PubMedCrossRef
24.
Oxman AD, Flottorp S, Havelsrud K, Fretheim A, Odgaard-Jensen J, Austvoll-Dahlgren A, et al. A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia. PloS One. 2007;2(10):e1040.
25.
Taibi DM, Vitiello MV, Barsness S, Elmer GW, Anderson GD, Landis CA. A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Med. 2009a;10(3):319–28.PubMedCrossRef
26.
Taavoni S, Ekbatani N, Kashaniyan M, Haghani H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause. 2011;18(9):951–5.PubMedCrossRef
27.
Taibi DM, Bourguignon C, Gill TA. A feasibility study of valerian extract for sleep disturbance in person with arthritis. Biol Res Nurs. 2009b;10(4):409–17.PubMedCrossRef
28.
Cuellar NG, Ratcliffe SJ. Does valerian improve sleepiness and symptom severity in people with restless legs syndrome? Altern Ther Health Med. 2009;15(2):22–8.
29.
Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000;33(2):47–53.PubMedCrossRef
30.
Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SR. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine. 2005;84(4):197–207.PubMedCrossRef
31.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.PubMedCrossRef
32.
Coxeter PD, Schluter PJ, Eastwood HL, Nikles CJ, Glasziou PP. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement Ther Med. 2003;11(4):215–22.PubMedCrossRef
33.
Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, et al. The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol. 2011;9(1):24–31.PubMedPubMedCentralCrossRef
34.
Smith T, Majid F, Eckl V, Morton RC. Herbal supplement sales in US increase by record-breaking 17.3% in 2020. Herbal Gram. 2021;131:52–65.
35.
Borras S, Martinez-Solis I, Rios JL. Medicinal plants for insomnia related to anxiety: an updated review. Planta Med. 2021;87(10-11):738–53.PubMed
36.
Poyares DR, Guilleminault C, Ohayon MM, Tufik S. Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal? Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):539–45.PubMedCrossRef
37.
Schulz H, Stolz C, Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry. 1994;27(4):147–51.PubMedCrossRef
38.
Ahmadi M, Khalili H, Abbasian L, Ghaeli P. Effect of valerian in preventing neuropsychiatric adverse effects of efavirenz in HIV-positive patients: a pilot randomized. Placebo-Controlled Clinical Trial Ann Pharmacother. 2017;51(6):457–64.PubMed
39.
Francis AJ, Dempster RJ. Effect of valerian, Valeriana edulis, on sleep difficulties in children with intellectual deficits: randomised trial. Phytomedicine. 2002;9(4):273–9.PubMedCrossRef
40.
Roh D, Jung JH, Yoon KH, Lee CH, Kang LY, Lee SK, et al. Valerian extract alters functional brain connectivity: a randomized double-blind placebo-controlled trial. Phytother Res. 2019;33(4):939–48.PubMedCrossRef
41.
Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology. 1985;87(4):406–9.PubMedCrossRef
42.
Huang HB, Sha R, Wan ZX. Effect of valerian on primary insomnia and endogenous plasma melatonin. Asia-Pacific Traditional Medicine. 2013;9(3):4–7.
43.
Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res. 2004;18(10):831–6.PubMedCrossRef
44.
Rechtschaffen A, Kales A. A manual of standardized terminology: techniques and scoring system for sleep stages in human subjects. UCLA Service/Brain Research Institute: Los Angeles; 1968.
45.
Reite M, Buysse D, Reynolds C, Mendelson W. The use of polysomnography in the evaluation of insomnia. Sleep. 1995;18(1):58–70.PubMedCrossRef
46.
47.
Sadeh A. The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev. 2011;15(4):259–67.PubMedCrossRef
48.
Lauderdale DS, Knutson KL, Yan LL, Liu K, Rathouz PJ. Self-reported and measured sleep duration: how similar are they? Epidemiol. 2008;19(6):838–45.CrossRef
49.
O'Donnell D, Silva EJ, Munch M, Ronda JM, Wang W, Duffy JF. Comparison of subjective and objective assessments of sleep in healthy older subjects without sleep complaints. J Sleep Res. 2009;18(2):254–63.PubMedPubMedCentralCrossRef
50.
Morin CM, Koetter U, Bastien C, Ware J, Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005;28:A251-A.CrossRef
51.
Asarnow LD. Depression and sleep: what has the treatment research revealed and could the HPA axis be a potential mechanism? Curr Opin Psychol. 2020;34:112–6.PubMedCrossRef
Metadaten
Titel
Valerian for Insomnia on Subjective and Objective Sleep Parameters: a Meta-analysis of Randomized Controlled Trials
verfasst von
Xu Zhang
Yanying Lu
Feiyan Lv
Yan Hu
Zhentao Yao
Yulong Wu
Fuzhi Lian
Jun Yang
Xianrong Xu
Publikationsdatum
16.06.2023
Verlag
Springer International Publishing
Erschienen in
Current Sleep Medicine Reports / Ausgabe 3/2023
Elektronische ISSN: 2198-6401
DOI
https://doi.org/10.1007/s40675-023-00259-4

Weitere Artikel der Ausgabe 3/2023

Error Propagation from Sleep Stage Classification to Derived Sleep Parameters in Machine Learning on Data from Wearables

  • Open Access

Insomnia and Hypoglossal Nerve Stimulation

Too Sour to be True? Tart Cherries (Prunus cerasus) and Sleep: a Systematic Review and Meta-analysis

  • Open Access

Longitudinal Management and a Decision-Aid Tool in Treatment-Resistant Sleep Apnea

  • Open Access

Co-morbid Insomnia and Sleep Apnoea (COMISA): Latest Research from an Emerging Field

  • Open Access

Digital Health Interventions for Insomnia: Turning Promise into Reality

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

Eine Therapie mit dem C40-Ligand-Blocker Frexalimab kann MS-Schübe und neue MRT-Läsionen über zwei Jahre hinweg verhindern. Dafür spricht die Auswertung einer offen fortgeführten Phase-2-Studie.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Positive Phase IIb-Studie zu spezifischer CAR-T-Zell-Therapie bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

Schadet Schichtarbeit dem Gehirn?

Eine große Registerstudie bestätigt, dass Schichtarbeit mit einem erhöhten Risiko für psychische und neurologische Erkrankungen einhergeht, sowie mit einer Volumenabnahme in Gehirnarealen, die für Depression, Angst und kognitive Funktionen relevant sind.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise